Insuman Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to global growth in diabetes cases, clinical reliability of human insulin, hospital based insulin therapy, affordability compared to analogs, long term physician trust.

The growth in the forecast period can be attributed to increasing type 2 diabetes incidence, expanding access in emerging markets, public healthcare insulin procurement, rising elderly population, structured diabetes care initiatives. Major trends in the forecast period include continued use of human insulin, rising diabetes prevalence, cost sensitive insulin prescribing, preference for established insulin brands, expansion of diabetes management programs.

The rising prevalence of diabetes is expected to drive the growth of the Insuman market. Diabetes, or diabetes mellitus, is a chronic metabolic disorder characterized by high blood glucose levels caused by insufficient insulin production by the pancreas or the body’s cells becoming resistant to insulin's effects. If left unmanaged, it can lead to serious complications affecting various organs. The increasing incidence of diabetes is primarily driven by poor dietary habits, excessive consumption of processed foods and sugary drinks, and sedentary lifestyles with minimal physical activity. Additionally, the aging population and family history of diabetes contribute to the risk, indicating a genetic predisposition. Insuman helps manage blood sugar levels in individuals with type 1 and type 2 diabetes by providing insulin, a hormone the body either doesn’t produce enough of or can’t use effectively. For example, in June 2024, The National Health Service (NHS England) reported that the number of individuals identified as having pre-diabetes in England rose to 3,615,330 in 2023, marking an 18% increase from 3,065,825 in 2022. Among those under 40, cases surged nearly 25%, growing from 173,166 in 2022 to 216,440 in 2023. As a result, the increasing prevalence of diabetes is driving the growth of the Insuman market.

The growing prevalence of obesity worldwide is expected to propel the growth of the Insuman market. Obesity is increasingly linked to changes in global food systems and eating habits, marked by higher consumption of ultra-processed foods, sedentary lifestyles, and economic factors that make unhealthy food choices more accessible. Obesity is a significant risk factor for type 2 diabetes, and Insuman, a form of human insulin, is often used to manage diabetes in obese individuals. Insulin therapy helps regulate blood sugar levels, although it requires careful monitoring, as insulin can sometimes contribute to weight gain. For example, in May 2024, the Office for Health Improvement and Disparities, a UK government department overseeing public health policies, reported that between 2022 and 2023, approximately 64% of adults aged 18 and older in England were classified as overweight or living with obesity, a figure comparable to the 63.8% reported the previous year. As such, the rising number of obesity cases globally is driving the growth of the Insuman market.

In November 2024, Amundi SA, a France-based asset management company offering investment management services, acquired shares in Sanofi SA. This acquisition is part of Amundi's strategy to strengthen its leadership in asset management and pursue responsible investment approaches, specifically through its significant stake in Sanofi SA. Sanofi, also based in France, is a pharmaceutical company specializing in biologics and vaccines, including human insulin.

Major companies operating in the insuman market are Sanofi S.A.

North America was the largest region in the insuman market in 2025. The regions covered in the insuman market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the insuman market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the insuman market by increasing costs for active pharmaceutical ingredients, insulin vial packaging, and international distribution. Hospital and retail pharmacy segments in europe and asia pacific are most affected due to global insulin supply chains. These tariffs may influence insulin affordability in public health systems. At the same time, tariffs are promoting local insulin manufacturing and improving regional self reliance for essential diabetes therapies.

The insuman market research report is one of a series of new reports that provides insuman market statistics, including insuman industry global market size, regional shares, competitors with a insuman market share, detailed insuman market segments, market trends and opportunities, and any further data you may need to thrive in the insuman industry. This insuman market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Insuman is a synthetic form of human insulin used to regulate blood sugar levels in individuals with diabetes mellitus. It is structurally identical to natural human insulin and is designed to replace or supplement the body’s insulin production, helping to manage blood glucose levels effectively. Insuman is available in multiple formulations tailored to meet the diverse needs of patients.

The main patient demographics for Insuman include pediatric patients, adult patients, and elderly patients. Pediatric patients, who are children and adolescents, require specialized care for various conditions, and Insuman provides formulations designed to address the specific needs of children with diabetes. The distribution channels for Insuman include hospitals, retail pharmacies, specialty pharmacies, and online pharmacies. It is used to treat conditions such as type 1 diabetes, type 2 diabetes, and gestational diabetes.

The insuman market consists of sales of insuman rapid, insuman basal, and insuman comb formulations, available in cartridges for reusable pens, prefilled disposable pens, and vials for syringe use. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.